Review





Similar Products

iwp4  (TargetMol)
92
TargetMol iwp4
Iwp4, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iwp4/product/TargetMol
Average 92 stars, based on 1 article reviews
iwp4 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
iwp4  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc iwp4
A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
Iwp4, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iwp4/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
iwp4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
wnt inhibitor iwp4  (Biogems International)
93
Biogems International wnt inhibitor iwp4
A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
Wnt Inhibitor Iwp4, supplied by Biogems International, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wnt inhibitor iwp4/product/Biogems International
Average 93 stars, based on 1 article reviews
wnt inhibitor iwp4 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
iwp4 13954  (Cayman Chemical)
90
Cayman Chemical iwp4 13954
A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
Iwp4 13954, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iwp4 13954/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
iwp4 13954 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
iwp4  (ReproCELL)
90
ReproCELL iwp4
A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
Iwp4, supplied by ReproCELL, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iwp4/product/ReproCELL
Average 90 stars, based on 1 article reviews
iwp4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
iwp4  (Cayman Chemical)
90
Cayman Chemical iwp4
A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
Iwp4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iwp4/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
iwp4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or IWP4 (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.

Journal: bioRxiv

Article Title: Preconditioning of human iPSCs with doxorubicin causes genome-wide transcriptional reprogramming in iPSC-derived cardiomyocytes linked to mitochondrial dysfunction and impaired cardiac regeneration

doi: 10.1101/2025.04.18.649376

Figure Lengend Snippet: A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or IWP4 (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.

Article Snippet: From day 4 to day 5, 1x B-27 supplement without insulin (ThermoFisher), 50 μg / mL ascorbic acid (Sigma-Aldrich) and 5 μM IWP4 (STEMCELL Technologies Inc.) was added to CBM.

Techniques: Comparison, Control, Derivative Assay, MTT Assay